Malignant News and Research

RSS

St. Luke’s offers Frameless Stereotactic Radiosurgery for treatment of brain tumors

Some treatments for brain and spine tumors traditionally have involved restraining a patient with a heavy immobilization device and pins that pierce the skin and embed into the skull to ensure the accuracy and precision of a treatment. Doctors say the pins can add considerable anxiety.

20 Jan 2015

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy.

20 Jan 2015

Study unveils genetic architecture that enables parasite to develop antimalarial drug resistance

The largest genome-wide association study to date of the malaria parasite Plasmodium falciparum unveils a complex genetic architecture that enables the parasite to develop resistance to our most effective antimalarial drug, artemisinin. The results could help to improve early detection of emerging artemisinin resistance.

20 Jan 2015

New study characterizes genetic underpinnings of phyllodes tumors

A new study from researchers at the University of Michigan Comprehensive Cancer Center characterizes the genetic underpinnings of a rare type of breast tumor called phyllodes tumors, offering the first comprehensive analysis of the molecular alterations at work in these tumors.

16 Jan 2015

Researchers identify new target that could lead to potential therapies for GBM

Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute for Molecular Medicine have identified a new protein-protein interaction that could serve as a target for future therapies for the most common form of brain cancer, glioblastoma multiforme (GBM).

14 Jan 2015

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.

14 Jan 2015

British Skin Foundation urges people to check their loved ones moles this Valentine’s Day

Valentine’s Day is fast approaching and this year the British Skin Foundation is urging people to check your loved ones moles! Whether it’s your boyfriend, girlfriend, spouse, friend or family – take the time to check for changes in moles.

12 Jan 2015

Research findings may lead to new therapeutic target for AML treatment

A study by the Cancer Science Institute of Singapore at the National University of Singapore has found new interactions between two molecules involved in acute myeloid leukaemia (AML), STAT3 and PRL-3, which may offer a new therapeutic target for cancer treatment.

12 Jan 2015

ULB researchers uncover new mechanism involved in tumour initiation, growth in SCC

Researchers at the Université libre de Bruxelles (Belgium) report the mechanisms regulating the different functions of Twist1 controlling skin tumour initiation, cancer stem cell function and tumor progression.

12 Jan 2015

New guidance recommends use of primary HPV test for cervical cancer screening

About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test.

8 Jan 2015

Adding radiation treatment to hormone therapy saves older men with prostate cancer

Adding radiation treatment to hormone therapy saves more lives among older men with locally advanced prostate therapy than hormone therapy alone, according to a new study in the Journal of Clinical Oncology this week from Penn Medicine researchers.

6 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.

6 Jan 2015

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute.

25 Dec 2014

Next generation sequencing in malignant pleural mesothelioma tumors reveals complex mutational setting

Next generation sequencing in malignant pleural mesothelioma (MPM) tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival and cell proliferation pathways. Increased accumulation of mutations correlates with early progression of the tumor and decreased survival.

23 Dec 2014

TUM researchers discover new mechanism for regulating programmed cell death

Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves. It serves a number of purposes in the body, including the prevention of malignant tumor growth. Now, researchers at Technische Universität München have discovered a previously unknown mechanism for regulating programmed cell death.

18 Dec 2014

University Hospital Bonn to validate accuracy of VolitionRx’s Nucleosomics technology in lung cancer

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that the University Hospital Bonn in Germany will initiate a clinical confirmatory study to assess VolitionRx’s proprietary Nucleosomics platform technology for the diagnosis of lung cancer through a blood test in individuals.

18 Dec 2014

New study identifies how SNAIL gene helps cancer cells break free from primary tumor

More than 90 percent of cancer-related deaths are caused by the spread of cancer cells from their primary tumor site to other areas of the body. A new study has identified how one important gene helps cancer cells break free from the primary tumor.

18 Dec 2014

Scientists produce novel class of molecules that could help combat cancer, other diseases

Promising treatments known as biologics are on the market and under development for many serious illnesses such as cancer, but some of them come with high risks, even lethal ones. Now scientists have produced a novel class of molecules that could be as effective but without the dangerous side effects.

17 Dec 2014

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.

16 Dec 2014

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

16 Dec 2014

Malignant News and Research

St. Luke’s offers Frameless Stereotactic Radiosurgery for treatment of brain tumors

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Study unveils genetic architecture that enables parasite to develop antimalarial drug resistance

New study characterizes genetic underpinnings of phyllodes tumors

Researchers identify new target that could lead to potential therapies for GBM

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

British Skin Foundation urges people to check their loved ones moles this Valentine’s Day

Research findings may lead to new therapeutic target for AML treatment

ULB researchers uncover new mechanism involved in tumour initiation, growth in SCC

New guidance recommends use of primary HPV test for cervical cancer screening

Adding radiation treatment to hormone therapy saves older men with prostate cancer

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Next generation sequencing in malignant pleural mesothelioma tumors reveals complex mutational setting

TUM researchers discover new mechanism for regulating programmed cell death

University Hospital Bonn to validate accuracy of VolitionRx’s Nucleosomics technology in lung cancer

New study identifies how SNAIL gene helps cancer cells break free from primary tumor

Scientists produce novel class of molecules that could help combat cancer, other diseases

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News